Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

This study is testing whether adding an immunotherapy drug (zimberelimab) to standard chemotherapy before surgery can better treat locally advanced cervical cancer by shrinking tumors more effectively prior to definitive treatment. **You may be eligible if...** - You are a woman 18 years or older - You have been diagnosed with squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix confirmed by biopsy - Your cervical cancer is locally advanced (FIGO stage IB3 or IIA2) and has not been treated yet - Your general health is good (ECOG score 0–1) - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have already received treatment for cervical cancer - You have severe autoimmune conditions - You have uncontrolled hepatitis B infection - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.